Q4 2024 Earnings Call Transcript February 26, 2025 Vir Biotechnology, Inc. beats earnings expectations. Reported EPS is ...

The breast cancer market has experienced robust growth, fueled by increased awareness and early detection efforts. Advances in diagnostic and treatment technologies have opened new avenues for ...

This study compared the carbon footprint of SC and IV administration using pertuzumab/trastuzumab as a case example. A Life Cycle Assessment was conducted to compare the environmental impacts of IV ...

and earlier this year launched a phase 3 study in previously untreated patients – DESTINY-Breast09 – which is comparing Enhertu with or without Roche's Perjeta (pertuzumab) to Perjeta ...

For HER2-positive breast cancers, additions included pertuzumab, ado-trastuzumab emtansine, and neratinib. The CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib were approved for HR ...